Teva Announces Suspension of Marketing for Zecuity for the Treatment of Migraine

Teva Pharmaceuticals, the manufacturer of Zecuity (sumatriptan iontophoretic transdermal system), has announced a voluntary suspension of sales, marketing, and distribution of the migraine patch due to the risk of serious burns and potential permanent scarring.

The Food and Drug Administration (FDA) reports that a larger number of patients have reported experiencing burns and scarring on the area where the patch was worn since this treatment became available in September 2015. FDA reports included descriptions of severe redness, pain, discoloration of the skin, blistering, and cracked skin.

Teva is advising patients to discontinue the use of Zecuity and discuss alternative treatment options with their physicians at this time.

Patients and Health Care Professionals should report any suspected side effects to Teva at 1-800-896-5855 or to the FDA at 1-800-FDA-1088. Reports can also be made via the FDA’s MedWatch Adverse Event Reporting Program at: www.fda.gov/medwatch/report.htm.

Additional information can be found on the FDA’s website: http://www.fda.gov/Drugs/DrugSafety/ucm504588.htm

It is critical that you do not stop, start, or change your medications without consulting with your healthcare provider.

Comments

View Comments (2)

Poll